Literature DB >> 19728400

Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes?

Lieve Desbonnet1, John L Waddington, Colm M P O Tuathaigh.   

Abstract

Schizophrenia is a complex neuropsychiatric disorder whose etiology involves a mixture of genetic and environmental factors. By virtue of this complexity, schizophrenia is a field of research in which a number of key technologies converge: in particular, identification of putative susceptibility genes through association studies in clinical populations leads to investigation of the behavioural roles of these genes by targeted manipulation in mice and their phenotypic characterisation ('gene-driven' approach); in a complementary manner, identification of putative pathophysiological processes and therapeutic pathways leads to investigation of behavioural phenotype in mice mutant for genes regulating such processes and pathways ('phenotype-driven' approach). As several susceptibility genes for schizophrenia and numerous genes implicated in the pathophysiology of schizophrenia have now been genetically manipulated in mice, it is timely to consider the roles of these genes in abnormal brain development and the ontogeny of putative schizophrenia-like phenotypes. The aim of this review is to outline existing knowledge from mutant studies concerning the contribution of these genes to the development of a common schizophrenia phenotype vis-à-vis discrete schizophrenia endophenotypes. Emphasis is also placed on the importance of studying gene x environment and gene x gene interactions, as well as addressing methodological issues related to genetic modelling and phenotyping strategies.

Entities:  

Mesh:

Year:  2009        PMID: 19728400     DOI: 10.1016/j.bbr.2009.04.001

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  17 in total

Review 1.  The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.

Authors:  Holly Moore
Journal:  Schizophr Bull       Date:  2010-09-24       Impact factor: 9.306

2.  mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.

Authors:  Martin Engel; Peta Snikeris; Natalie Matosin; Kelly Anne Newell; Xu-Feng Huang; Elisabeth Frank
Journal:  Psychopharmacology (Berl)       Date:  2016-02-10       Impact factor: 4.530

3.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

4.  Attenuation of cocaine-induced conditioned locomotion is associated with altered expression of hippocampal glutamate receptors in mice lacking LPA1 receptors.

Authors:  Eduardo Blanco; Ainhoa Bilbao; María Jesús Luque-Rojas; Ana Palomino; Francisco J Bermúdez-Silva; Juan Suárez; Luis J Santín; Guillermo Estivill-Torrús; Antonia Gutiérrez; José Angel Campos-Sandoval; Francisco J Alonso-Carrión; Javier Márquez; Fernando Rodríguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  2011-09-02       Impact factor: 4.530

Review 5.  Animal models of gene-environment interaction in schizophrenia: A dimensional perspective.

Authors:  Yavuz Ayhan; Ross McFarland; Mikhail V Pletnikov
Journal:  Prog Neurobiol       Date:  2015-10-25       Impact factor: 11.685

Review 6.  Mutant mouse models: phenotypic relationships to domains of psychopathology and pathobiology in schizophrenia.

Authors:  Colm M P O'Tuathaigh; John L Waddington
Journal:  Schizophr Bull       Date:  2010-02-12       Impact factor: 9.306

Review 7.  Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia.

Authors:  Darrick T Balu; Joseph T Coyle
Journal:  Neurosci Biobehav Rev       Date:  2010-10-15       Impact factor: 8.989

8.  Chronic adolescent exposure to Δ-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes.

Authors:  Colm M P O'Tuathaigh; Magdalena Hryniewiecka; Aine Behan; Orna Tighe; Catherine Coughlan; Lieve Desbonnet; Mary Cannon; Maria Karayiorgou; Joseph A Gogos; David R Cotter; John L Waddington
Journal:  Neuropsychopharmacology       Date:  2010-07-14       Impact factor: 7.853

Review 9.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

10.  GABAergic deficits in absence of LPA1 receptor, associated anxiety-like and coping behaviors, and amelioration by interneuron precursor transplants into the dorsal hippocampus.

Authors:  Cristina Rosell-Valle; Magdalena Martínez-Losa; Elisa Matas-Rico; Estela Castilla-Ortega; Emma Zambrana-Infantes; Ana Isabel Gómez-Conde; Lourdes Sánchez-Salido; David Ladrón de Guevara-Miranda; Carmen Pedraza; Pedro Jesús Serrano-Castro; Jerold Chun; Fernando Rodríguez de Fonseca; Manuel Álvarez-Dolado; Luis Javier Santín; Guillermo Estivill-Torrús
Journal:  Brain Struct Funct       Date:  2021-04-01       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.